nVerses Capital’s Bioventus BVS Stock Holding History

nVerses Capital’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18,484	Closed	-$169K	–	321
2026 Q1	$169K	Buy	+18,484	New	+$155K	0.15%	289

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

nVerses Capital's BVS Position: Q2 2026 in Review

nVerses Capital sold out of Bioventus (BVS) in Q2 2026, closing a stake of 18,484 shares — an estimated $169K sold.

nVerses Capital first reported a position in BVS in Q1 2026 and held it in 1 quarter. The position peaked at $169K in Q1 2026. 106 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

nVerses Capital reported no remaining Bioventus position as of Q2 2026 after selling out during the quarter.
nVerses Capital sold 18,484 Bioventus shares in Q2 2026, an estimated $169K.
nVerses Capital first reported a position in Bioventus in Q1 2026 and held it in 1 quarter.
nVerses Capital's Bioventus position peaked at $169K in Q1 2026.
106 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.